Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Macor

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Immunology Letters|June 19, 2007
Complement as effector system in cancer immunotherapyPaolo Macor, Francesco Tedesco
Frontiers in Immunology|October 16, 2018
Complement as a Biological Tool to Control Tumor GrowthPaolo Macor, Sara Capolla, Francesco Tedesco
Frontiers in Pharmacology|October 4, 2023
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapyFederico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 17, 2013
Phage display technology for human monoclonal antibodiesCecilia Deantonio, Diego Cotella, Paolo Macor, et al.
International Journal of Molecular Sciences|September 9, 2022
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative TherapiesMonica Mossenta, Davide Busato, Michele Dal Bo, et al.
International Journal of Molecular Sciences|September 23, 2022
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal AdenocarcinomaDavide Busato, Monica Mossenta, Michele Dal Bo, et al.
Pharmaceutics|August 28, 2021
Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal ModelSara Bozzer, Michele Dal Bo, Giuseppe Toffoli, et al.
European Journal of Immunology|June 23, 2005
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59Federica Ziller, Paolo Macor, Roberta Bulla, et al.
Developmental and Comparative Immunology|November 1, 2019
Complement system and phagocytosis in a colonial protochordateAnna Peronato, Laura Drago, Ute Rothbächer, et al.
Arthritis and Rheumatism|March 30, 2007
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in ratsFabio Fischetti, Paolo Durigutto, Paolo Macor, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Immunology Letters|June 19, 2007
Complement as effector system in cancer immunotherapyPaolo Macor, Francesco Tedesco
Frontiers in Immunology|October 16, 2018
Complement as a Biological Tool to Control Tumor GrowthPaolo Macor, Sara Capolla, Francesco Tedesco
Frontiers in Pharmacology|October 4, 2023
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapyFederico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 17, 2013
Phage display technology for human monoclonal antibodiesCecilia Deantonio, Diego Cotella, Paolo Macor, et al.
International Journal of Molecular Sciences|September 9, 2022
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative TherapiesMonica Mossenta, Davide Busato, Michele Dal Bo, et al.
International Journal of Molecular Sciences|September 23, 2022
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal AdenocarcinomaDavide Busato, Monica Mossenta, Michele Dal Bo, et al.
Pharmaceutics|August 28, 2021
Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal ModelSara Bozzer, Michele Dal Bo, Giuseppe Toffoli, et al.
European Journal of Immunology|June 23, 2005
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59Federica Ziller, Paolo Macor, Roberta Bulla, et al.
Developmental and Comparative Immunology|November 1, 2019
Complement system and phagocytosis in a colonial protochordateAnna Peronato, Laura Drago, Ute Rothbächer, et al.
Arthritis and Rheumatism|March 30, 2007
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in ratsFabio Fischetti, Paolo Durigutto, Paolo Macor, et al.
Pageof 8